BEAM THERAPEUTICS INC.
StreetZero Signal 60
About BEAM THERAPEUTICS INC.
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. Founded by leading scientists in CRISPR gene editing, the company is pursuing therapies using its proprietary base editors that create precise, predictable single base changes at targeted genomic locations. Beam has assembled an integrated platform including gene editing, delivery and internal manufacturing capabilities. The company is headquartered in Cambridge, Massachusetts and is publicly traded on NASDAQ under the ticker BEAM.
LATEST FUNDINGRule 144
$600K
Announced 2026-10-16
TOTAL RAISED$222M
IN THE NEWS
- 🔗 Beam Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street - Sixth Street
- 🔗 Beam Therapeutics Announces Pricing of Initial Public Offering
- 🔗 Beam Therapeutics Announces Closing of Initial Public Offering – IPO Edge
- 🔗 Beam Therapeutics Announces Pricing of Underwritten Offering | Beam Therapeutics
EMPLOYEES—
FOUNDED2017
HQCambridge, MA, United States
Industry
Public Equity (NASDAQ)
Tags
BiotechnologyGene EditingCRISPRPublic
Key highlights
- Raised $222M across four rounds with latest post-IPO financing in 2021.
- Completed IPO in 2020 pricing 12.2M shares at $17 per share.
- Developing base-editing platform for precise single-base genomic changes.
- Secured $500M strategic financing facility with Sixth Street in 2025.
- Maintains 18 institutional investors and integrated manufacturing capabilities.
Ask StreetZero about BEAM THERAPEUTICS INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account